Key Takeaways Facial/neck lesions show the highest response rates to tacrolimus 0.1%, often with early perifollicular islands of repigmentation. Trunk/extremities […]
Key Takeaways Adding topical tacrolimus to NB-UVB is associated with higher facial response rates and earlier perifollicular repigmentation in many
Key Takeaways Excimer 308 nm is well suited for localized/focal lesions, particularly on the face and neck, enabling targeted high-fluence delivery
Key Takeaways NB-UVB achieves comparable or superior facial repigmentation versus PUVA in multiple comparative studies, with fewer systemic adverse effects.
Key Takeaways NB-UVB (311–313 nm) consistently induces clinically meaningful repigmentation across multiple cohorts; face responds best, acral sites worst. Typical regimens
Key Takeaways Vitiligo imposes a clinically meaningful quality-of-life (QoL) burden; facial and visible-area involvement, rapid progression, and darker phototypes are
Key Takeaways Clinical diagnosis is usually sufficient; bedside confirmation relies on sharply demarcated depigmentation and accentuation under Wood’s lamp. Dermoscopy
Key Takeaways Lesional and perilesional skin frequently shows elevated H2O2 and reduced catalase activity, creating a pro-oxidant milieu hostile to
Key Takeaways Vitiligo is a complex, polygenic disorder with loci mapping to immune regulation (e.g., HLA, NLRP1, PTPN22, IL2RA) and
Key Takeaways Vitiligo is driven by cytotoxic, melanocyte-reactive T cells orchestrated by an IFN-γ → CXCL9/10 → CXCR3 chemokine circuit.